Comparable Effectiveness of First Week Treatment with Anti-Staphylococcal Penicillin versus Cephalosporin in Methicillin-Sensitive Staphylococcus aureus Bacteremia : A Propensity-Score Adjusted Retrospective Study

Show full item record



Permalink

http://hdl.handle.net/10138/172703

Citation

Forsblom , E S , Ruotsalainen , E & Jarvinen , A 2016 , ' Comparable Effectiveness of First Week Treatment with Anti-Staphylococcal Penicillin versus Cephalosporin in Methicillin-Sensitive Staphylococcus aureus Bacteremia : A Propensity-Score Adjusted Retrospective Study ' , PLoS One , vol. 11 , no. 11 , 0167112 . https://doi.org/10.1371/journal.pone.0167112

Title: Comparable Effectiveness of First Week Treatment with Anti-Staphylococcal Penicillin versus Cephalosporin in Methicillin-Sensitive Staphylococcus aureus Bacteremia : A Propensity-Score Adjusted Retrospective Study
Author: Forsblom, Erik Sebastian; Ruotsalainen, Eeva; Jarvinen, Asko
Contributor: University of Helsinki, Clinicum
University of Helsinki, Infektiosairauksien yksikkö
University of Helsinki, Department of Medicine
Date: 2016-11-29
Language: eng
Number of pages: 13
Belongs to series: PLoS One
ISSN: 1932-6203
URI: http://hdl.handle.net/10138/172703
Abstract: The objective was to compare the prognostic impact of first week treatment with anti-staphylococcal penicillin (ASP) versus cephalosporin in methicillin-sensitive Staphylococcus aureus bacteremia (MS-SAB). Altogether 580 patients were retrospectively followed and categorized according to first week treatment; 84% (488) received ASP (cloxacillin) and 16% (92) cephalosporin (cefuroxime or ceftriaxone). SAB management was optimized with formal bedside infectious disease specialist consultation in 88%, deep infection foci diagnosed in 77% and adjunctive rifampicin therapy given to 61% of patients. The total case fatality in 580 patients was 12% at 28 days and 18% at 90 days. When comparing effectiveness of first week ASP versus cephalosporin treatment there were no significant differences in 28-days (11% vs. 12%, OR; 1.05, 95% CI, 0.53-2.09) or 90-days (17% vs. 21% OR; 1.25, 95% CI, 0.72-2.19) outcome. In univariate analysis no prognostic impact of either first week ASP or cephalosporin treatment was observed for 28-days (OR; 0.96, 95% CI, 0.48-1.90 and OR; 1.05, 95% CI, 0.53-2.09) or 90-days (OR; 0.80, 95% CI, 0.46-1.39 and OR; 1.25, 95% CI, 0.72-2.19) outcome. Propensity-score adjusted Cox proportional regression analysis for first week treatment with cephalosporin demonstrated no significant prognostic impact at 28-days (HR 1.54, 95% CI 0.72-3.23) or 90-days (HR 1.56, 95% CI 0.88-2.86). In conclusion: There is a comparable effectiveness with respect to 28- and 90-days outcome for first week treatment with ASP versus cephalosporin in MS-SAB. The results indicate that the difference in prognostic impact between first week ASP and cephalosporin may be nonsignificant in patient cohorts with SAB management optimized by infectious disease specialist consultation.
Subject: CEFAZOLIN
COHORT
CARE
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
file.pdf 1.679Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record